




Instance: composition-en-b3a525a247bab07c652b4fb8f5f55618
InstanceOf: CompositionUvEpi
Title: "Composition for vizamyl Package Leaflet"
Description:  "Composition for vizamyl Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/14/941/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpb3a525a247bab07c652b4fb8f5f55618)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vizamyl"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What VIZAMYL is and what it is used for </li>
<li>What you need to know before VIZAMYL is used </li>
<li>How VIZAMYL is used </li>
<li>Possible side effects </li>
<li>How VIZAMYL is stored </li>
<li>Contents of the pack and other information  </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What vizamyl is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vizamyl is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>VIZAMYL contains the active substance flutemetamol (18F) and is used to help diagnose Alzheimer s 
disease and other causes of memory loss.<br />
This medicine is a radiopharmaceutical product for diagnostic use only. </p>
<p>VIZAMYL is used to help diagnose Alzheimer s disease and other causes of memory loss. It is given 
to adults with memory problems before they undergo a type of brain scan called a positron-emission 
tomography (PET) scan. This scan, along with other brain function tests, can help your doctor 
determine whether or not you may have  -amyloid plaques in your brain.  -Amyloid plaques are 
deposits sometimes present in the brains of people with dementias (such as Alzheimer s disease).  </p>
<p>You should discuss the results of the test with the doctor that requested the scan. </p>
<p>The use of VIZAMYL involves exposure to small amounts of radioactivity. Your doctor and the 
nuclear medicine doctor have considered that the clinical benefit of this procedure with the 
radiopharmaceutical outweighs the risk of being exposed to these small amounts of radiation. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vizamyl"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vizamyl"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>VIZAMYL must not be used:</p>
<ul>
<li>If you are allergic to flutemetamol (18F) or any of the other ingredients of this medicine (listed in 
section 6). </li>
</ul>
<p>Warnings and precautions 
Talk to your nuclear medicine doctor before you are given VIZAMYL if you:</p>
<ul>
<li>have kidney problems </li>
<li>have liver problems </li>
<li>are pregnant or think you may be pregnant </li>
<li>are breast-feeding </li>
</ul>
<p>Children and adolescents 
VIZAMYL is not intended for use in children and adolescents below the age of 18 years old. </p>
<p>Other medicines and VIZAMYL 
Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other 
medicines since they may interfere with the images obtained from the brain scan. </p>
<p>Pregnancy and breast-feeding 
You must inform the nuclear medicine doctor before you are given VIZAMYL if there is a possibility 
you might be pregnant, if you have missed your period or if you are breast-feeding. When in doubt, it 
is important to consult the nuclear medicine doctor who will supervise the procedure.  </p>
<p>If you are pregnant 
The nuclear medicine doctor will only give this medicine during pregnancy if a benefit is expected 
which would outweigh the risks.  </p>
<p>If you are breast-feeding 
You must stop breast-feeding for 24 hours after the injection. Express the breast milk during this 
period and discard any breast milk you have expressed. Resuming breast-feeding should be in 
agreement with the nuclear medicine doctor who will supervise the procedure.  </p>
<p>You should avoid any close contact with young children for 24 hours following the injection. </p>
<p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your nuclear medicine doctor for advice before you are given this medicine. </p>
<p>Driving and using machines 
VIZAMYL may cause transient dizziness or vertigo, which may affect your ability to drive or use 
machines. You should not drive, use machines or engage in other potentially hazardous activities until 
these effects have completely disappeared. </p>
<p>VIZAMYL contains alcohol (ethanol) and sodium 
VIZAMYL contains alcohol (ethanol). Each dose contains up to 552 mg alcohol. This is about the 
same as 14 mL of beer or 6 mL of wine. This could be harmful for people with alcoholism and needs 
to be taken into account in pregnant or breast-feeding women and people with liver problems or 
epilepsy. </p>
<p>VIZAMYL contains a maximum of 41 mg of sodium (main component of cooking/table salt) in each 
dose. This is equivalent to approximately 2% of the adult recommended maximum daily dietary intake 
for sodium  These amounts may need to be considered for people on a low sodium diet. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vizamyl"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vizamyl"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>There are strict laws on the use, handling and disposal of radiopharmaceutical products. 
VIZAMYL will only be used in special controlled areas. This product will only be handled and given 
to you by professionals who are trained and qualified to use it safely. They will provide you with the 
necessary information on the procedure. </p>
<p>Your nuclear medicine doctor may ask you to drink plenty of water before the start of the examination 
and the 24 hours after the study in order to urinate as often as possible to help remove it from your 
body faster.  </p>
<p>Dose 
The nuclear medicine doctor supervising the procedure will decide on the amount of VIZAMYL to be 
used in your case. The doctor will choose the smallest amount necessary.  </p>
<p>The usual amount recommended for an adult is 185 MBq. Megabecquerel (MBq) is the unit used to 
measure radioactivity. </p>
<p>Administration of VIZAMYL and conduct of the procedure 
VIZAMYL is given as an injection into your vein (intravenous injection) followed by a flush of 
sodium chloride solution to ensure full delivery of the dose. </p>
<p>One injection is sufficient to carry out the scan that your doctor needs. </p>
<p>Duration of the procedure 
A brain scan is usually taken 90 minutes after VIZAMYL is given. Your nuclear medicine doctor will 
inform you about the usual duration of the procedure.  </p>
<p>After administration of VIZAMYL 
You should avoid any close contact with young children and pregnant women for 24 hours following 
the injection. </p>
<p>The nuclear medicine doctor will inform you if you need to take any special precautions after 
receiving this medicine. Contact your nuclear medicine doctor if you have any questions. </p>
<p>If you have received more VIZAMYL than you should 
An overdose is unlikely since you will only receive a single dose of VIZAMYL from the nuclear 
medicine doctor under controlled conditions. </p>
<p>However, in the case of an overdose, you would receive the appropriate treatment. Treatment consists 
of increasing the passing of urine and stools in order to help remove radioactivity from your body. </p>
<p>If you have any further questions on the use of this medicine, please ask your nuclear medicine doctor 
who supervises the procedure. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. 
The following side effects may happen with this medicine: </p>
<p>Serious side effects 
Tell your doctor straight away, if you notice any of the following, as you may need urgent medical 
treatment:</p>
<ul>
<li>Allergic reactions - the signs may include swelling of your face or eyes, having pale, itchy or 
tight skin or having a rash, feeling short of breath, tightness in the chest, irritation in your throat 
or being sick. These are uncommon side effects and may affect up to 1 in 100 people. </li>
</ul>
<p>Tell your doctor straight away if you notice any of the signs above. </p>
<p>Other side effects include 
Common - may affect up to 1 in 10 people 
- looking flushed 
- increased blood pressure 
Uncommon - may affect up to 1 in 100 people. You may experience the following uncommon side 
effects:</p>
<ul>
<li>headache </li>
<li>feeling dizzy </li>
<li>feeling anxious </li>
<li>feeling sick (nausea) </li>
<li>chest discomfort </li>
<li>
<p>low blood sugar (symptoms: hunger, headache) </p>
</li>
<li>
<p>back pain </p>
</li>
<li>feeling hot or cold </li>
<li>increased breathing rate </li>
<li>pain at the injection site </li>
<li>heart pounding (palpitations) </li>
<li>pain in muscles or bones </li>
<li>shaking movements (tremor) </li>
<li>puffy and swollen skin  </li>
<li>fever </li>
<li>over breathing (hyperventilation) </li>
<li>change in the way you taste things </li>
<li>a spinning feeling (vertigo) </li>
<li>reduced sense of touch or sensation </li>
<li>feeling tired or weak </li>
<li>inability to get or maintain an erection </li>
<li>indigestion, stomach ache or sore mouth </li>
<li>vomiting </li>
<li>decreased feeling or sensitivity especially in your skin or your face </li>
<li>increase in  blood lactate dehydrogenase  or  neutrophils  in blood tests </li>
<li>skin tightness </li>
</ul>
<p>This radiopharmaceutical will deliver low amounts of ionising radiation, which is associated with very 
low risk of cancer and hereditary abnormalities (passing on faulty genes). </p>
<p>Reporting of side effects 
If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vizamyl"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vizamyl"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>You will not have to store this medicine. This medicine is stored under the responsibility of the 
specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national 
regulation on radioactive materials. </p>
<p>The following information is intended for the specialist only. </p>
<p>Do not use this medicine after the expiry date and time, which are stated on the label after  EXP . </p>
<p>Do not use this medicine if you notice that the vial is damaged or the solution contains particulate 
matter or appears discoloured. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What VIZAMYL contains 
- The active substance is flutemetamol (18F). Each mL of solution contains flutemetamol (18F) 
400 MBq at reference date and time. 
- The other ingredients are sodium chloride and ethanol anhydrous, polysorbate 80, sodium 
dihydrogen phosphate dihydrate, disodium hydrogen phosphate dodecahydrate and water for 
injections, see section 2. What VIZAMYL looks like and contents of the pack 
- VIZAMYL is a clear, colourless to slightly yellow solution for injection. 
- VIZAMYL is supplied in a 10-mL or 15-mL glass vial. Each vial is stored in a container. 
- Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder </p>
<p>GE Healthcare AS 
Nycoveien 1<br />
NO-0485 Oslo<br />
Norway </p>
<p>Manufacturers 
Advanced Accelerator Applications Molecular 
Imaging Italy S.r.l. 
Via Piero Maroncelli 47014 Meldola (FC) 
Italy </p>
<p>Advanced Accelerator Applications Molecular 
Imaging France SAS 
Technopole de l Aube 
14 Rue Gustave Eiffel 
10430 Rosi res-Pr s-Troyes 
France </p>
<p>Seibersdorf Labor GmbH 
Grundstuck. Nr. 482/2 EZ98 KG 
2444 Seibersdorf 
Austria </p>
<p>Curium PET France 
Parc scientifique Georges Besse 
180 allee Von Neumann 
30000 N mes 
France 
Curium Pharma Spain, S.A.<br />
C/Manuel Bartolome Cossio 28040 Madrid 
Spain </p>
<p>Curium Italy S.R.L. 
Via Ripamonti 20141 Milano (MI) 
Italy </p>
<p>Advanced Accelerator Applications Molecular 
Imaging Iberica S.L.U.<br />
Josep Anselm Clav  Esplugues de Llobregat 
Barcelona, 08Spain </p>
<p>Advanced Accelerator Applications Molecular 
Imaging Italy S.R.L.<br />
Via Dell  Industria,<br />
86077 Pozzilli (IS) 
Italy  </p>
<p>Curium Finland Oy 
Saukonpaadenranta 2 
Helsinki, FI-00Finland </p>
<p>Nucleis SA 
All e du Six-Ao t, 8 
4000 Li ge<br />
Belgium </p>
<p>Helmholtz-Zentrum Dresden-Rossendorf e.V. 
Zentrum f r Radiopharmazeutische 
Tumorforschung 
Bautzner Landstra e 01328 Dresden 
Germany </p>
<p>ITEL Telecomunicazioni S.r.l. 
Via Antonio Labriola Zona Industriale SNC<br />
70037, Ruvo di Puglia (BA)<br />
Italy </p>
<p>La Maddalena SPA 
Via San Lorenzo Colli, 312/D 
90146 Palermo (PA) 
Italy </p>
<p>Advanced Accelerator Applications Molecular 
Imaging Iberica S.L.U. 
Hospital Clinico Universitario Virgen de la 
Arrixaca, Ctra. Madrid-Cartagena, sn, El Palmar, 
30120 Murcia 
Spain 
This leaflet was last revised in {month YYYY}. </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p> </div>"""      



Instance: composition-da-b3a525a247bab07c652b4fb8f5f55618
InstanceOf: CompositionUvEpi
Title: "Composition for vizamyl Package Leaflet"
Description:  "Composition for vizamyl Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/14/941/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpb3a525a247bab07c652b4fb8f5f55618)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vizamyl"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du bliver undersøgt med VIZAMYL 
3. Sådan skal VIZAMYL bruges 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p> </div>"""   
          

* section[=].section[+]
  * title =  "1. What vizamyl is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vizamyl is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>VIZAMYL indeholder det aktive stof flutemetamol (18F) og bruges til at hjælpe med til at 
diagnosticere Alzheimers sygdom og andre årsager til hukommelsestab.<br />
Dette produkt er et radioaktivt lægemiddel og er kun til diagnostisk brug. </p>
<p>VIZAMYL bruges til at hjælpe med til at diagnosticere Alzheimers sygdom og andre årsager til 
hukommelsestab. Det gives til voksne personer med hukommelsesproblemer, før de gennemgår en 
form for hjernescanning som kaldes en positron-emission tomografi (PET) scanning. Denne scanning 
kan sammen med andre funktionstest af hjernen hjælpe din læge med at afgøre, hvorvidt du kan have 
β- amyloid plak i din hjerne. Β-amyloid plak er aflejringer som undertiden er til stede i hjernen hos 
mennesker med demenssygdomme (såsom Alzheimers sygdom).  </p>
<p>Du bør diskutere resultaterne af scanningen med den læge, der har anmodet om scanningen. </p>
<p>Anvendelse af VIZAMYL indebærer, at du udsættes for små mængder radioaktivitet. Din læge og den 
nuklearmedicinske læge har vurderet at de kliniske fordele ved denne undersøgelse med det 
radioaktive lægemiddel, overstiger risikoen for at blive udsat for disse små mængder stråling.  </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vizamyl"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vizamyl"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>VIZAMYL må ikke bruges hvis:</p>
<ul>
<li>du er allergisk over for flutemetamol (18F) eller nogle af de øvrige indholdsstoffer i lægemidlet 
(de er angivet i afsnit 6). </li>
</ul>
<p>Advarsler og forholdsregler<br />
Tal med din nuklearmedicinske læge før VIZAMYL bliver givet til dig, hvis:</p>
<ul>
<li>du har en nyresygdom </li>
<li>du har en leversygdom </li>
<li>du er gravid eller tror, du er gravid  </li>
<li>du ammer </li>
</ul>
<p>Børn og unge<br />
VIZAMYL må ikke anvendes til børn og unge under 18 år. 
Brug af anden medicin sammen med VIZAMYL 
Fortæl din nuklearmedicinske læge, hvis du tager anden medicin eller har gjort det for nylig. Andre 
lægemidler kan påvirke billederne fra hjernescanningen. </p>
<p>Graviditet og amning 
Fortæl det til din nuklearmedicinske læge, før du får injektionen med VIZAMYL, hvis der er 
mulighed for, at du er gravid, hvis din menstruation er udeblevet, eller hvis du ammer. Hvis du er i 
tvivl, er det vigtigt, at du rådfører dig med den nuklearmedicinske læge, der skal overvåge proceduren.  </p>
<p>Hvis du er gravid 
Den nuklearmedicinske lægen vil kun give dette lægemiddel under graviditet, hvis de forventede 
fordele overstiger risiciene.  </p>
<p>Hvis du ammer 
Du skal ophøre med at amme i 24 timer efter injektionen. Udpump modermælk i løbet af denne 
periode, og kassér modermælk, du har udpumpet. Genoptagelsen af amningen skal ske efter aftale med 
den nuklearmedinske læge, som er ansvarlig for undersøgelsen.  </p>
<p>Du bør undgå enhver tæt kontakt med små børn 24 timer efter injektionen. </p>
<p>Hvis du er gravid eller mener at være gravid eller har planer om at få et barn, skal du spørge den 
nuklearmedicinske læge, inden du får givet dette lægemiddel. </p>
<p>Trafik- og arbejdssikkerhed 
VIZAMYL kan forårsage forbigående svimmelhed og balanceproblemer, der kan påvirke din evne til 
at køre eller betjene maskiner. Du bør ikke køre bil, betjene maskiner eller deltage i andre potentielt 
farlige aktiviteter, før disse symptomer er gået fuldstændig over. </p>
<p>VIZAMYL indeholder alkohol (ethanol) og natrium (salt) 
VIZAMYL indeholder alkohol (ethanol). Hver dosis indeholder op til 552 mg alkohol. Dette svarer 
omtrentligt til 14 ml øl eller 6 ml vin. Det kan være skadeligt for personer med et alkoholmisbrug, og 
det skal også tages i betragtning for gravide eller ammende og personer med leversygdomme eller 
epilepsi. 
VIZAMYL indeholder maksimalt 41 mg natrium (hovedkomponenten i madlavnings/bord salt) per 
dosis. Dette svarer til ca. 2% af det anbefalede maksimale daglige indtag af natrium for en voksen. 
Denne mængde skal tages med i overvejelserne hos personer, som er på en diæt med lavt saltindhold. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vizamyl"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vizamyl"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Der findes en restriktiv lovgivning vedrørende anvendelse, håndtering og bortskaffelse af radioaktive 
lægemidler.<br />
VIZAMYL må kun anvendes indenfor områder med speciel kontrol. Dette produkt må kun håndteres 
og gives til dig af professionelle personer, som er trænede og kvalificerede til at bruge det sikkert. De 
vil holde dig informeret om, hvad der sker. </p>
<p>Den nuklearmedicinske læge kan bede dig om at drikke rigeligt vand før undersøgelsen og i 24 timer 
efter undersøgelsen for at muliggøre hyppig vandladning, så produktet fjernes hurtigst muligt fra din 
krop. </p>
<p>Dosis 
Den nuklearmedicinske læge vil afgøre, hvilken dosis VIZAMYL, der passer bedst til dig. Lægen vil 
vælge den mindste nødvendige dosis. 
Den normalt anbefalede mængde til en voksen er 185 MBq. Megabecquerel (MBq) er den målenhed, 
som anvendes til måling af radioaktivitet. </p>
<p>Administration af VIZAMYL og udførelse af proceduren 
VIZAMYL bliver givet til dig som en injektion i venen (intravenøs injektion) efterfulgt af en skylning 
med natriumkloridopløsning for at sikre, at den fulde dosis er indgivet.  </p>
<p>Én injektion er tilstrækkelig til at udføre den scanning, den nuklearmedicinske læge skal bruge. </p>
<p>Procedurens varighed 
En scanning af hjernen udføres normalt 90 minutter efter indgivelsen af VIZAMYL.<br />
Den nuklearmedicinske læge vil informere dig om procedurens normale varighed.  </p>
<p>Efter administration af VIZAMYL 
Skal du undgå tæt kontakt med små børn og gravide kvinder i de næstfølgende 24 timer efter 
injektionen. </p>
<p>Den nuklearmedicinske læge vil informere dig, hvis du skal tage særlige forholdsregler efter at have 
fået indgivet lægemidlet. Kontakt den nuklearmedicinske læge i tilfælde af spørgsmål. </p>
<p>Hvis du har fået mere VIZAMYL, end du burde 
En overdosis er usandsynligt, da du kun vil få en enkelt dosis VIZAMYL fra den nuklearmedicinske 
læge under kontrollerede forhold. 
Hvis det imidlertid skulle ske, vil din nuklearmedicinske læge sørge for, at du får en passende 
behandling. Behandlingen består i at øge vandladning og afføring for at hjælpe med at fjerne 
radioaktiviteten fra kroppen. </p>
<p>Hvis du har flere spørgsmål til brugen af dette lægemiddel, kan du spørge din nuklearmedicinske læge. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.<br />
Følgende bivirkninger kan opleves, når du tager dette lægemiddel: </p>
<p>Alvorlige bivirkninger 
Fortæl det omgående til den nuklearmedicinske læge, hvis du bemærker noget af det følgende, da du 
måske behøver akut medicinsk behandling:</p>
<ul>
<li>Allergiske reaktioner - symptomerne kan være hævelse af dit ansigt eller dine øjne, din hud 
bliver bleg, kløende eller stram, eller du får udslæt, åndenød, stramhed i brystet, halsirritation, 
eller du føler dig dårlig tilpas. Disse er ikke almindelige og kan forekomme hos 1 ud af personer. </li>
</ul>
<p>Andre bivirkninger inkluderer 
Almindelige - kan forekomme hos 1 ud af 10 personer 
- rødme 
- forhøjet blodtryk </p>
<p>Ikke almindelig - kan forekomme hos 1 ud af 100 personer. Du kan muligvis opleve følgende ikke 
almindelige bivirkninger:</p>
<ul>
<li>hovedpine </li>
<li>svimmelhed </li>
<li>angstfornemmelse </li>
<li>utilpashed (kvalme) </li>
<li>ubehag i brystet </li>
<li>lavt blodsukker (symptom: sultfølelse, hovedpine) </li>
<li>rygsmerter </li>
<li>varme- eller kuldefølelse </li>
<li>øget vejrtrækning </li>
<li>smerter ved injektionsstedet </li>
<li>dunkende hjerte (hjertebanken) </li>
<li>smerter i led eller muskler </li>
<li>rysten (tremor) </li>
<li>oppustet eller opsvulmet hud </li>
<li>feber </li>
<li>hyppig vejrtrækning (hyperventilation) </li>
<li>ændret smagsfornemmelse </li>
<li>balanceproblemer (svimmelhed) </li>
<li>nedsat føle- eller berøringssans </li>
<li>træthedsfølelse, svaghedsfølelse </li>
<li>mistet evne til at få eller opretholde en rejsning (erektion) </li>
<li>fordøjelsesbesvær, mavepine eller ømhed i munden </li>
<li>opkastning </li>
<li>nedsat følesans, særligt i hud eller ansigt </li>
<li>forøget "laktat dehydrogenase i blodet" eller forøget antal "neutrofiler", påvist ved en blodprøve </li>
<li>stram hud </li>
</ul>
<p>Dette radioaktive lægemiddel vil udsende små mængder ioniserende stråling, som er forbundet med 
meget lav risiko for cancer og arvelige sygdomme (overført til defekte gener). </p>
<p>Indberetning af bivirkninger<br />
Hvis du oplever bivirkninger, bør du tale med din nuklearmedicinske læge, sygeplejerske eller 
apoteket. Dette gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du 
eller dine pårørende kan også indberette bivirkninger direkte til Sundhedsstyrelsen via det nationale 
rapporteringssystem anført i Appendiks V. 
Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden 
af dette lægemiddel. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vizamyl"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vizamyl"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du skal ikke opbevare dette lægemiddel. Dette lægemiddel opbevares på en dertil bestemt lokalitet 
under ansvar af specialisten. Opbevaring af radioaktive lægemidler foregår i henhold til nationale 
bestemmelser vedrørende radioaktive materialer. </p>
<p>Følgende information er udelukkende beregnet for specialisten. </p>
<p>Brug ikke lægemidlet efter udløbsdatoen, som står på etiketten efter "UDLØBDATO". </p>
<p>Lægemidlet må ikke anvendes, hvis hætteglasset er beskadiget, eller hvis opløsningen indeholder 
partikler eller er misfarvet. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad VIZAMYL indeholder 
- VIZAMYL indeholder det aktive stof flutemetamol (18F). Hver ml af opløsningen indeholder 
flutemetamol (18F) 400 MBq på referencedatoen og -tidspunktet.<br />
- De andre indholdsstoffer er natriumklorid og ethanol anhydrid (se afsnit 2 under 'VIZAMYL' 
indeholder alkohol (ethanol) og natrium), polysorbat 80, natriumdihydrogenfosfatdihydrat, 
dinatriumhydrogenfosfatdodecahydrat og vand til injektion, se afsnit 2. Udseende af VIZAMYL og pakkens indhold 
- VIZAMYL er en klar, farveløs til let gullig opløsning beregnet til injektion. 
- VIZAMYL leveres i et 10 ml eller 15 ml hætteglas. Hvert hætteglas opbevares i en beholder. 
- Ikke alle emballagestørrelser er nødvendigvis markedsført. </p>
<p>Indehaveren af markedsføringstilladelsen: 
GE Healthcare AS 
Nycoveien 1<br />
NO-0485 Oslo 
Norge </p>
<p>Fremstiller 
Advanced Accelerator Applications Molecular 
Imaging Italy S.r.l. 
Via Piero Maroncelli 47014 Meldola (FC) 
Italien </p>
<p>Advanced Accelerator Applications Molecular 
Imaging France SAS (AAA) 
Technopole de l’Aube 
14 Rue Gustave Eiffel 
10430 Rosières-Près-Troyes 
Frankrig </p>
<p>Seibersdorf Labor GmbH 
Grundstuck. Nr. 482/2 EZ98 KG 
2444 Seibersdorf 
Østrig </p>
<p>Curium PET France 
Parc scientifique Georges Besse 
180 allee Von Neumann 
30000 Nîmes 
Frankrig 
Curium Pharma Spain, S.A. 
C/Manuel Bartolome Cossio 28040 Madrid 
Spanien </p>
<p>Curium Italy S.R.L. 
Via Ripamonti 20141 Milano (MI) 
Italien </p>
<p>Advanced Accelerator Applications Molecular 
Imaging Iberica, S.L.U. <br />
Josep Anselm Clavé Esplugues de Llobregat 
Barcelona, 08Spanien </p>
<p>Advanced Accelerator Applications Molecular 
Imaging Italy S.R.L.<br />
Via Dell’ Industria 
86077 Pozzilli (IS) 
Italien  </p>
<p>Curium Finland Oy 
Saukonpaadenranta 2 
Helsinki, FI-00Finland </p>
<p>Nucleis SA 
Allée du Six-Août, 8 
4000 Liège<br />
Belgien </p>
<p>Helmholtz-Zentrum Dresden-Rossendorf e.V. 
Zentrum für Radiopharmazeutische 
Tumorforschung 
Bautzner Landstraβe 01328 Dresden 
Tyskland </p>
<p>ITEL Telecomunicazioni S.r.l. 
Via Antonio Labriola Zona Industriale SNC 
70037, Ruvo di Puglia (BA)<br />
Italien </p>
<p>La Maddalena SPA 
Via San Lorenzo Colli, 312/D 
90146 Palermo (PA) 
Italien </p>
<p>Advanced Accelerator Applications Molecular 
Imaging Iberica S.L.U. 
Hospital Clinico Universitario Virgen de la 
Arrixaca, Ctra. Madrid-Cartagena, sn, El Palmar, 
30120 Murcia 
Spanien  </p>
<p>Denne indlægsseddel blev sidst ændret i {måned ÅÅÅÅ}. </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/. </p>
<p>Nedenstående oplysninger er til læger og sundhedspersonale: </p>
<p>Det fuldstændige produktresumé for VIZAMYL findes som et separat dokument i produktpakken med 
det formål at give læger og sundhedspersonale yderligere videnskabelige og praktiske oplysninger om 
administration og brug af radioaktive lægemidler. </p>
<p>Se produktresuméet {produktresuméet findes i æsken}. </p> </div>"""      





                    
Instance: bundlepackageleaflet-en-b3a525a247bab07c652b4fb8f5f55618
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for vizamyl Package Leaflet for language en"
Description: "ePI document Bundle for vizamyl Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-b3a525a247bab07c652b4fb8f5f55618"
* entry[0].resource = composition-en-b3a525a247bab07c652b4fb8f5f55618

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpb3a525a247bab07c652b4fb8f5f55618"
* entry[=].resource = mpb3a525a247bab07c652b4fb8f5f55618
                            
                    
Instance: bundlepackageleaflet-da-b3a525a247bab07c652b4fb8f5f55618
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for vizamyl Package Leaflet for language da"
Description: "ePI document Bundle for vizamyl Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-b3a525a247bab07c652b4fb8f5f55618"
* entry[0].resource = composition-da-b3a525a247bab07c652b4fb8f5f55618

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpb3a525a247bab07c652b4fb8f5f55618"
* entry[=].resource = mpb3a525a247bab07c652b4fb8f5f55618
                            
                    



Instance: mpb3a525a247bab07c652b4fb8f5f55618
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product VIZAMYL 400 MBq/mL solution for injection"
Description: "VIZAMYL 400 MBq/mL solution for injection"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/14/941/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "VIZAMYL 400 MBq/mL solution for injection"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: b3a525a247bab07c652b4fb8f5f55618ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "vizamyl"

* status = #current
* mode = #working

* title = "List of all ePIs associated with vizamyl"

* subject = Reference(mpb3a525a247bab07c652b4fb8f5f55618)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#vizamyl "vizamyl"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-b3a525a247bab07c652b4fb8f5f55618) // vizamyl en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-b3a525a247bab07c652b4fb8f5f55618) // vizamyl da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-b3a525a247bab07c652b4fb8f5f55618
InstanceOf: List

* insert b3a525a247bab07c652b4fb8f5f55618ListRuleset
    